Pfizer Enters into Research Consortium to Expand Understanding of Diabetes and Obesity Pathobiology
Pfizer has entered into a collaboration agreement with four major research universities â University of California, Santa Barbara (UCSB); Caltech; the Massachusetts Institute of Technology; and University of Massachusetts â and Entelos, a physiological modeling company, to re-examine the regulatory mechanisms of human energy metabolism.
Read more ...
Two Merck Medicines Recommended for Approval in the European Union
Merck & Co., Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended two medicines for marketing approval in the European Union (EU).
Read more ...
GlaxoSmithKline will acquire Sirtris Pharmaceuticals for approximately USD720 million
GlaxoSmithKline (NYSE: GSK) and Sirtris Pharmaceuticals Incorporated (Nasdaq: SIRT) announced that they have entered into a definitive agreement pursuant to which GlaxoSmithKline will acquire Sirtris Pharmaceuticals for approximately USD720 million (or approx. GBP362 million) through a cash tender offer of USD22.50 (or approx. GBP11.33) per share.
Read more ...
AstraZeneca PLC First Quarter Results 2008
Sales in the first quarter increased by 4 percent at CER, or 10 percent on an as reported basis. Sales in the US were up 5 percent; the inclusion of MedImmune sales in the quarter more than offset the decline in Toprol-XL™ sales in the US market.
Read more ...
Genzyme Reports Strong First-Quarter Growth
Genzyme Corporation (NASDAQ: GENZ) reported results for the first quarter of 2008, which featured excellent revenue growth, continued operating leverage, a significant increase in non-GAAP profit, and strong progress across the company.
Read more ...
Novartis reports higher sales and earnings in first quarter of 2008
On track for solid growth in 2008, Novartis reported higher net sales and double-digit earnings growth in the first quarter of 2008 from the Group's continuing operations now entirely focused on healthcare and reaffirmed its outlook for record sales and earnings for the full year.
Read more ...
Novartis announces 20% average reduction in price of malaria drug Coartem®
Novartis has announced a 20% average reduction in the price of Coartem® tablets (artemether/lumefantrine 20 mg/120 mg), the state-of-the-art artemisinin-based combination treatment (ACT) for malaria. Starting this Friday, which is World Malaria Day, this price reduction will increase access to Coartem for millions of malaria patients, especially children in low income regions of Africa.
Read more ...